-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, the 2021 annual reports of 32 listed companies focusing on the pharmaceutical business sector have been releas.
Among them, in terms of revenue, 18 companies exceeded 10 billion yu.
Shanghai Pharmaceuticals and Jointown have outstanding performance, with revenue reaching 21824 billion yuan and 12407 billion yuan respectively in 202 According to the 2021 performance report data released by Shanghai Pharmaceuticals, the company's operating income in 2021 will increase by 146% year-on-year to 21824 billion yu.
Among them, the revenue of the pharmaceutical industry increased by 71% year-on-year to 2098 billion yuan; the revenue of the pharmaceutical business increased by 142% year-on-year to 19726 billion yu.
In 2021, Shanghai Pharma's net profit attributable to the parent company will increase by 128% year-on-year to 093 billion yuan; net profit attributable to the parent company after deducting non-deductibles will increase by 7% year-on-year to 001 billion yu.
According to the 2021 performance report released by Jointown, the annual operating income of Jointown in 2021 will increase by 142% year-on-year to 12407 billion yuan, a new hi.
Regarding the revenue growth of Shanghai Pharmaceuticals and Jointown, the report of Shanghai Ocean Pharmaceuticals shows that in 2021, Shanghai Pharmaceuticals will continue to increase its efforts in innovation and transformation, in new vaccine businesses, pharmaceutical industry R&D innovation, pharmaceutical business model innovation, system and mechanism innovation and many other aspec.
Get gratifying resul.
Among them, in the pharmaceutical business business, the Shanghai Pharmaceutical Network directly covers 24 provinces and cities across the count.
In 2021, the company has newly obtained the general agent qualification for 18 imported new drugs, and the imported vaccine agency business has also achieved sales revenue of about 3 billion yu.
In order to strengthen sustainable development capabilities, the company is committed to creating a new round of growth engine through business model innovati.
Among them, the company has launched innovative drug full life cycle management services to build a full life cycle service system including pre-market clinical trial supply chain support, new drug import and out-of-hospital market services, innovative financial payment services, national hospital market distribution and mature drug general contracti.
The operating highlights of Jointown in 2021 are outstanding: Among them, the "Wandian Alliance" plan is progressing rapidly, and 6,138 self-operated and franchised pharmacies have been realized, covering 28 provinces and cities across the country, and it is expected to exceed 10,000 by the end of 2022; "BC Warehouse Distribution" The "integration" project is advancing rapidly, and 4 integrated BC warehouses in Guangdong, Shanghai, Jiangsu, and Hubei have been put into operation, with a daily collection rate of over 99%; a breakthrough has been made in the construction of the "Power Health" service platform for the C-side, and the company's first An Internet hospital license, released the "Power Health" V0 APP (including the user terminal and the doctor terminal), and reached a strategic cooperation agreement with Ant Insuran.
The above operating highlights have boosted the company's performance to continue to improve, and accelerated the company's business transformation and upgradi.
It is understood that in addition to the outstanding performance of the above two companies in operating income in 2021, the company also showed a good trend in the first quarter of 202 Among them, in the first quarter of 2022, Shanghai Pharmaceuticals achieved a year-on-year increase of 127% in operating income to 5898 billion yuan; net profit attributable to the parent after deduction increased by 98% year-on-year to 250 billion yu.
It is understood that in the first quarter of 2022, the sales revenue of 60 key products of Shanghai pharmaceutical industry increased by 105% year-on-year to 033 billion yu.
There are 47 new drug pipelines under development, of which 39 are innovative drug pipelines and 8 are improved new drug pipelines; in terms of the consistency evaluation of generic drugs, 6 new varieties (7 product specifications) have been added, resulting in a cumulative increase of over-evaluated produc.
to 43 varieties (62 gauge.
In the first quarter of 2022, due to the disappearance of some incidental and non-sustainable factors that caused the adverse effects of the fourth quarter of last year, the company's operating performance showed a recovery growth compared with the same period of the previous year, and its operating income increased by 73% year-on-year to 3150 billion yuan ; Net profit attributable to the parent after deduction of non-deductible items increased by 152% year-on-year to 477 million yu.
This growth provides a solid foundation for the company's performance growth for the full year 202 It is understood that the pharmaceutical retail business is an important part of the main business of Jointo.
The company makes full use of the advantages of the existing supply chain, through the "integration of wholesale and retail" and the combination of online and offline models, to empower the company's retail business and expand company digital reta.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, in terms of revenue, 18 companies exceeded 10 billion yu.
Shanghai Pharmaceuticals and Jointown have outstanding performance, with revenue reaching 21824 billion yuan and 12407 billion yuan respectively in 202 According to the 2021 performance report data released by Shanghai Pharmaceuticals, the company's operating income in 2021 will increase by 146% year-on-year to 21824 billion yu.
Among them, the revenue of the pharmaceutical industry increased by 71% year-on-year to 2098 billion yuan; the revenue of the pharmaceutical business increased by 142% year-on-year to 19726 billion yu.
In 2021, Shanghai Pharma's net profit attributable to the parent company will increase by 128% year-on-year to 093 billion yuan; net profit attributable to the parent company after deducting non-deductibles will increase by 7% year-on-year to 001 billion yu.
According to the 2021 performance report released by Jointown, the annual operating income of Jointown in 2021 will increase by 142% year-on-year to 12407 billion yuan, a new hi.
Regarding the revenue growth of Shanghai Pharmaceuticals and Jointown, the report of Shanghai Ocean Pharmaceuticals shows that in 2021, Shanghai Pharmaceuticals will continue to increase its efforts in innovation and transformation, in new vaccine businesses, pharmaceutical industry R&D innovation, pharmaceutical business model innovation, system and mechanism innovation and many other aspec.
Get gratifying resul.
Among them, in the pharmaceutical business business, the Shanghai Pharmaceutical Network directly covers 24 provinces and cities across the count.
In 2021, the company has newly obtained the general agent qualification for 18 imported new drugs, and the imported vaccine agency business has also achieved sales revenue of about 3 billion yu.
In order to strengthen sustainable development capabilities, the company is committed to creating a new round of growth engine through business model innovati.
Among them, the company has launched innovative drug full life cycle management services to build a full life cycle service system including pre-market clinical trial supply chain support, new drug import and out-of-hospital market services, innovative financial payment services, national hospital market distribution and mature drug general contracti.
The operating highlights of Jointown in 2021 are outstanding: Among them, the "Wandian Alliance" plan is progressing rapidly, and 6,138 self-operated and franchised pharmacies have been realized, covering 28 provinces and cities across the country, and it is expected to exceed 10,000 by the end of 2022; "BC Warehouse Distribution" The "integration" project is advancing rapidly, and 4 integrated BC warehouses in Guangdong, Shanghai, Jiangsu, and Hubei have been put into operation, with a daily collection rate of over 99%; a breakthrough has been made in the construction of the "Power Health" service platform for the C-side, and the company's first An Internet hospital license, released the "Power Health" V0 APP (including the user terminal and the doctor terminal), and reached a strategic cooperation agreement with Ant Insuran.
The above operating highlights have boosted the company's performance to continue to improve, and accelerated the company's business transformation and upgradi.
It is understood that in addition to the outstanding performance of the above two companies in operating income in 2021, the company also showed a good trend in the first quarter of 202 Among them, in the first quarter of 2022, Shanghai Pharmaceuticals achieved a year-on-year increase of 127% in operating income to 5898 billion yuan; net profit attributable to the parent after deduction increased by 98% year-on-year to 250 billion yu.
It is understood that in the first quarter of 2022, the sales revenue of 60 key products of Shanghai pharmaceutical industry increased by 105% year-on-year to 033 billion yu.
There are 47 new drug pipelines under development, of which 39 are innovative drug pipelines and 8 are improved new drug pipelines; in terms of the consistency evaluation of generic drugs, 6 new varieties (7 product specifications) have been added, resulting in a cumulative increase of over-evaluated produc.
to 43 varieties (62 gauge.
In the first quarter of 2022, due to the disappearance of some incidental and non-sustainable factors that caused the adverse effects of the fourth quarter of last year, the company's operating performance showed a recovery growth compared with the same period of the previous year, and its operating income increased by 73% year-on-year to 3150 billion yuan ; Net profit attributable to the parent after deduction of non-deductible items increased by 152% year-on-year to 477 million yu.
This growth provides a solid foundation for the company's performance growth for the full year 202 It is understood that the pharmaceutical retail business is an important part of the main business of Jointo.
The company makes full use of the advantages of the existing supply chain, through the "integration of wholesale and retail" and the combination of online and offline models, to empower the company's retail business and expand company digital reta.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
